Aptar Pharma's Preservative-Free Multidose Dispenser Chosen for the First Time for a Prescription Dry Eye Product in the US w...
March 22 2017 - 5:00PM
Business Wire
Aptar Pharma’s innovative and patented preservative-free
multidose Ophthalmic Squeeze Dispenser is available for patients in
the U.S. prescription market for the first time with Allergan’s
RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170322006214/en/
Courtesy of Allergan
This approval and launch makes the Aptar Pharma Ophthalmic
Squeeze Dispenser the very first, and only, U.S. FDA-approved
multidose delivery system to handle prescription eye treatment
formulations without any preservatives.
Meeting the needs of patients
Aptar Pharma is working closely with eye care specialist
Allergan to improve patient safety, achieve dosing accuracy and
maintain product integrity.
Dry eye patients use eye drops on a regular basis, and often for
the rest of their lives. It is well-proven that preserved
medications may cause unpleasant and sometimes serious side
effects.
FDA approval
The increasing number of patients experiencing eye irritation or
allergic reactions with preserved formulations appreciate the fact
that preservatives can be removed from eye care medications with
Aptar Pharma’s Ophthalmic Squeeze Dispenser system. RESTASIS® and
RESTASIS MULTIDOSE™ are FDA-approved prescription treatments to
help patients suffering from Chronic Dry Eye to make more of their
own tears.
Making ophthalmic solutions easier and safer to
deliver
Aptar Pharma’s Ophthalmic Squeeze Dispenser system is the result
of more than 10 years of development and experience in the delivery
of preservative-free ophthalmic solutions. Patients and consumers
in Europe, Latin America and Asia have benefited from this
technology since 2012 with more than 100 commercial references now
available on the market.
RESTASIS® is not an artificial tear. It is a prescription
medicine that helps increase the eyes' natural ability to produce
tears.
“Our Ophthalmic Squeeze Dispenser technology has been a great
success for our customers,” explained Salim Haffar, President,
Aptar Pharma. “The proven and unrivalled microbiological safety,
combined with a precise and reproducible drop ejection allows
pharmaceutical customers worldwide to enter into discussions with
regulatory agencies such as the FDA.” Mr. Haffar also points out
the user-friendliness of the system, “The ergonomic and pocket-size
design and the intuitiveness of a squeezable container with a low
actuation force certainly contribute to the high levels of
acceptance among patients and consumers around the world.”
Staying ahead of the market
Aptar Pharma's Ophthalmic Squeeze Dispenser provides a unique
competitive advantage by addressing the global trend towards
patient-friendly, cost-effective and preservative-free multidose
dispensers.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading
global supplier of a broad range of innovative dispensing and
sealing solutions for the beauty, personal care, home care,
prescription drug, consumer health care, injectables, food and
beverage markets. AptarGroup is headquartered in Crystal Lake,
Illinois, with manufacturing facilities in North America, Europe,
Asia and South America. For more information, visit
www.aptar.com.
This press release contains forward-looking statements. Words
such as “expects,” “anticipates,” “believes,” “estimates,” “future”
and other similar expressions or future or conditional verbs such
as “will,” “should,” “would” and “could” are intended to identify
such forward-looking statements. Forward-looking statements are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and are based on our beliefs as well as assumptions
made by and information currently available to us. Accordingly, our
actual results may differ materially from those expressed or
implied in such forward-looking statements due to known or unknown
risks and uncertainties that exist in our operations and business
environment. Additionally, forward-looking statements include
statements that do not relate solely to historical facts, such as
statements which identify uncertainties or trends, discuss the
possible future effects of current known trends or uncertainties or
which indicate that the future effects of known trends or
uncertainties cannot be predicted, guaranteed or assured. For
additional information on these and other risks and uncertainties,
please see our filings with the Securities and Exchange Commission,
including the discussion under “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” in our Form 10-Ks and Form 10-Qs. We undertake no
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170322006214/en/
Media Contact:Carolyn
PenotAptar Pharma+33 1 39 17 20
38carolyn.penot@aptar.comorInvestor
Relations Contact:Matthew DellaMariaAptarGroup, Inc.815
479 5530matt.dellamaria@aptar.com
AptarGroup (NYSE:ATR)
Historical Stock Chart
From Mar 2024 to Apr 2024
AptarGroup (NYSE:ATR)
Historical Stock Chart
From Apr 2023 to Apr 2024